Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 09, 2016 4:29 PM ET

Life Sciences Tools and Services

Company Overview of Furiex Pharmaceuticals, Inc.

Company Overview

Furiex Pharmaceuticals, Inc. operates as a drug development company that is involved in compound development and collaboration activities primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company holds rights to royalties and regulatory and sales-based milestone payments for alogliptin, alogliptin combination products, and SYR-472 (trelagliptin) for the treatment of Type-2 diabetes, which are marketed under the Nesina and Liovel names in Japan, as well as under the Nesina, Oseni, and Kazano names in the United States. It also owns rights to royal...

3900 Paramount Parkway

Suite 150

Morrisville, NC 27560

United States

Founded in 1998

24 Employees



Key Executives for Furiex Pharmaceuticals, Inc.

Chief Financial Officer, Principal Accounting Officer and Vice President of Strategic Development
Age: 57
Senior Vice President of Clinical Development & Operations
Age: 59
Associate Director of Preclinical Development
Executive Director of Clinical Operations
Compensation as of Fiscal Year 2015.

Furiex Pharmaceuticals, Inc. Key Developments

Furiex Pharmaceuticals, Inc.(NasdaqGM:FURX) dropped from Russell 2000 Index

Furiex Pharmaceuticals, Inc. will be removed from the Russell 2000 Index.

Furiex Pharmaceuticals, Inc.(NasdaqGM:FURX) dropped from Russell 3000 Index

Furiex Pharmaceuticals, Inc. will be removed from the Russell 3000 Index.

Furiex Pharmaceuticals, Inc.(NasdaqGS:FURX) dropped from NASDAQ Composite Index

Furiex Pharmaceuticals, Inc. will be removed from the NASDAQ Composite Index.

Similar Private Companies By Industry

Company Name Region
Kronos Science Laboratories, Inc. United States
AssayGate, Inc. United States
Lab Vision Corporation United States
Mediatech, Inc. United States
SciLog, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Furiex Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at